Histiocytosis Program

Clinical trials

The main objective of the Histiocytosis Research Program is to improve the understanding and treatment of histiocytic disorders, especially Langerhans cell histiocytosis and Hemagophagocytic Lymphohistiocytosis. Program faculty actively contribute to and participate in internally led research initiatives as well as those directed by the Histiocyte Society, an international research collaboration.

Following are some of the research initiatives under way in the research program:

• Our program treats patients in accordance with protocols established by the Histiocyte Society. LCH and HLH patients are offered the opportunity to take part in clinical trials organized by the Histiocyte Society.
• A clinical database has been established to identify patterns of disease in patients with LCH and to determine the effectiveness of specific treatments.
• In collaboration with the laboratory of Barrett Rollins, MD, PhD, of Dana-Farber, the program is evaluating the biology of histiocytic disorders. If your child undergoes biopsies of histiocytic lesions, you may be offered the chance to participate in a study that uses tissue samples to learn more about the condition.

View clinical trials at Dana-Farber/Children's Hospital Cancer Center.